Abstract:Altered energy metabolism is a biochemical fingerprint of cancer cells that represents one of the “hallmarks of cancer”. This metabolic phenotype is characterized by preferential dependence on glycolysis (the process of conversion of glucose into pyruvate followed by lactate production) for energy production in an oxygen-independent manner. Although glycolysis is less efficient than oxidative phosphorylation in the net yield of adenosine triphosphate (ATP), cancer cells adapt to this mathematical disadvantage by increased glucose up-take, which in turn facilitates a higher rate of glycolysis. Apart from providing cellular energy, the metabolic intermediates of glycolysis also play a pivotal role in macromolecular biosynthesis, thus conferring selective advantage to cancer cells under diminished nutrient supply. Accumulating data also indicate that intracellular ATP is a critical determinant of chemoresistance. Under hypoxic conditions where glycolysis remains the predominant energy producing pathway sensitizing cancer cells would require intracellular depletion of ATP by inhibition of glycolysis. Together, the oncogenic regulation of glycolysis and multifaceted roles of glycolytic components underscore the biological significance of tumor glycolysis. Thus targeting glycolysis remains attractive for therapeutic intervention. Several preclinical investigations have indeed demonstrated the effectiveness of this therapeutic approach thereby supporting its scientific rationale. Recent reviews have provided a wealth of information on the biochemical targets of glycolysis and their inhibitors. The objective of this review is to present the most recent research on the cancer-specific role of glycolytic enzymes including their non-glycolytic functions in order to explore the potential for therapeutic opportunities. Further, we discuss the translational potential of emerging drug candidates in light of technical advances in treatment modalities such as image-guided targeted delivery of cancer therapeutics.

The therapeutic implications of immunosuppressive tumor aerobic glycolysis

Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment

Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target

Targeting glycolysis for cancer therapy using drug delivery systems

Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Tumor glycolysis as a target for cancer therapy: progress and prospects

Glycolysis, the sweet appetite of the tumor microenvironment

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment

Immunological Aspects of Cancer Cell Metabolism

T cell metabolic fitness in antitumor immunity

Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function

The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy

Tumor Energy Metabolism: Implications for Therapeutic Targets

The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities

A Novel Strategy to Fuel Cancer Immunotherapy: Targeting Glucose Metabolism to Remodel the Tumor Microenvironment

Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

Tumor microenvironment induced switch to mitochondrial metabolism promotes suppressive functions in immune cells

Therapeutic Targeting of Cancer Cell Metabolism

Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints